ArticleBMC cancer2025
Single-cell multi-omics analysis reveals drivers of intrahepatic cholangiocarcinoma metastasis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrahepatic cholangiocarcinoma (ICC) is a highly heterogeneous malignancy with poor prognosis, in which tumor metastasis represents a critical event driving disease progression and treatment failure. Understanding the cellular drivers of ICC metastasis and establishing effective risk assessment models are essential for improving patient outcomes.
methodsWe analyzed the GSE201425 single-cell RNA sequencing dataset to explore the cellular origins and mechanisms of ICC metastasis. Copy number variation (CNV) profiling and clonal evolution analysis were performed to identify malignant epithelial cells. Pseudotime trajectory analysis revealed metastasis-associated epithelial cells (MAECs). Key biomarkers within MAECs were screened, and a Metastasis Index (Met-Index) based on one-class logistic regression was constructed to assess metastasis risk in bulk RNA-seq data from the TCGA-CHOL cohort. Multiplex immunofluorescence staining was performed in 34 clinical ICC specimens. Functional validation was conducted in HuCCT1 cells using siRNA-mediated gene silencing, followed by CCK-8 proliferation assays and wound healing assays.
resultsMAECs were identified as a distinct epithelial subpopulation enriched in metastatic ICC samples. Biomarkers including MMP7, FXYD2, and PTHLH were upregulated in MAECs and strongly correlated with metastatic status. The Met-Index effectively stratified patients into high- and low-risk groups, with the high Met-Index group exhibiting significantly worse overall survival (p = 0.005) and progression-free survival (p = 0.015). Immunofluorescence validation confirmed increased expression of MMP7, FXYD2, and PTHLH in metastatic tumors, which correlated with advanced clinicopathological features. Functional assays demonstrated that knockdown of these biomarkers inhibited HuCCT1 cell proliferation and suppressed cell migration capacity.
conclusionsThis study delineates the cellular origin and molecular drivers of ICC metastasis at the single-cell level, identifies MAECs as a metastasis-related subpopulation, and establishes a clinically relevant Met-Index with prognostic value. These findings provide potential biomarkers and therapeutic targets for the early identification and management of ICC patients at high risk of metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.